Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-10-28 Capital/Financing Update
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet for a fixed rate note issuance by Sanofi, detailing terms such as principal amount, interest rate, maturity date, redemption options, and ratings. It is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. The content focuses on the specifics of a debt financing instrument and its issuance details, indicating it is an update on capital raising activity. The document length is 3811 characters, which is relatively short and consistent with a financing update rather than a full report. There is no financial statement or comprehensive financial analysis present, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of a report publication. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2025-10-28 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet for Sanofi's 2028 Floating Rate Notes, detailing terms such as principal amount, interest rate, maturity, redemption, and settlement dates. It is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. The content focuses on the specifics of a debt issuance and financing terms rather than financial results, management changes, or regulatory compliance filings. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 5735 characters, sufficient to contain detailed financing information rather than a brief announcement or a report publication notice. Therefore, the correct classification is CAP with high confidence.
2025-10-28 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet for a fixed rate note issuance by Sanofi, detailing terms such as principal amount, interest rate, maturity date, and underwriting banks. It is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. The content focuses on the capital raising activity and terms of the debt issuance, not on financial results, management changes, or regulatory compliance. The document length is 3721 characters, which is relatively short and typical for a financing update. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2025-10-28 English
FWP
Capital/Financing Update Classification · 100% confidence The document is a Pricing Term Sheet for a $500 million Floating Rate Notes issuance by Sanofi due 2027. It includes detailed terms of the debt issuance such as interest rate, maturity, redemption terms, and settlement dates. The document is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. This is a clear update on a capital raising activity and financing terms, not a financial report, earnings release, or regulatory filing unrelated to financing. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing terms, not just an announcement or a brief notice, so it is not an RPA or RNS. Confidence is high given the explicit nature of the content and regulatory references.
2025-10-28 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal declaration of share buyback transactions ('Déclaration des transactions sur actions propres') by Sanofi. It provides an aggregated summary by day and a detailed list of individual transactions, including transaction IDs, timestamps, prices, and quantities, in compliance with market regulations (MAR art. 5). This fits the definition of 'Transaction in Own Shares' (POS).
2025-10-27 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under a registration statement with the SEC. It details the offering of various floating rate and fixed rate notes, including terms, interest rates, redemption options, risk factors, underwriting, and other related information. The document is a preliminary prospectus supplement and prospectus for a debt securities offering, which is a capital raising activity. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or board changes. The content clearly relates to a financing update and capital raising through debt issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-10-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.